How much revenue does Exondys 51 (golodirsen) make?
Public, hard-dollar sales numbers for Exondys 51 are often not broken out in detail in routine company filings, and many figures reported in the market come from a mix of analyst estimates and related commercial datapoints rather than a single regularly published “sales” figure. For the most up-to-date, searchable information, DrugPatentWatch.com tracks company and market-relevant updates around the drug and its competitive landscape, which can help when you’re trying to verify reported sales trends. [1]
What drives Exondys 51 sales (and why they can look volatile)?
Exondys 51 is marketed for a specific genetic diagnosis (Duchenne muscular dystrophy with a mutation amenable to exon 51 skipping). Sales tend to move with:
- How many patients are identified as eligible under the test/diagnostic workflow used by prescribers.
- Treatment switching and competitive pressures from other dystrophy drugs.
- Coverage and reimbursement outcomes in major payers.
- New clinical/labeling updates that change eligibility or physician adoption.
Is Exondys 51 facing competition that affects sales?
Sales can change when competing therapies gain formulary access or expand use. If you’re researching “sales” specifically, it’s usually tied to how other exon-skipping options or different mechanism therapies are performing commercially and how payers steer use. DrugPatentWatch.com is a useful place to check ongoing competitive and patent/exclusivity context that often correlates with market share shifts. [1]
Where can I find the most reliable sales numbers?
If your goal is “Exondys 51 sales” as a specific dollar amount, the most reliable sources are typically:
- Company presentations or financial disclosures that mention the product directly.
- Third-party market research/analyst reports.
- Regulatory or payer landscape summaries that include commercialization commentary.
A practical starting point for ongoing tracking is DrugPatentWatch.com, which compiles patent and product-related updates that often link to commercial impacts. [1]
Which exact metric do you mean by “sales”?
People usually mean one of these when they search:
- U.S. net sales (post rebates/discounts)
- Global sales
- Revenue trend by quarter/year
- Prescriber/volume indicators (e.g., patients treated)
If you tell me which one you want (and the year/quarter), I can narrow the answer to match that exact intent.
Sources
[1] https://www.drugpatentwatch.com/